Pacira BioSciences (PCRX): Is There More Value to Unlock After Shares Nearly Double?

Pacira BioSciences (PCRX) has been making waves in investor circles lately, but it is not due to a single blockbuster announcement or game-changing report. Instead, recent moves in PCRX’s stock seem to be catching the attention of those looking for signals in the broader healthcare space. With no clear event driving the action, investors may be left wondering what is really behind the latest price swings and whether there is more beneath the surface. Looking at the past year, Pacira BioSciences shares have nearly doubled, showing a 98% climb. That kind of performance, especially after a period of longer-term underperformance, can shift sentiment quickly. While momentum is strong over the past month and quarter as well, this stands in stark contrast to a five-year return that is still negative for shareholders. It is worth noting that annual revenue growth has been steady, and net income growth has turned positive this year, painting a mixed but intriguing picture. After this kind of rebound, the big question is whether Pacira BioSciences is offering a genuine buying opportunity right now or if the market has already factored in all the potential future growth.

Most Popular Narrative: 9% Undervalued

According to the most widely followed analyst narrative, Pacira BioSciences is currently trading at a discount to its fair value estimate, driven by expectations of future earnings growth and market expansion catalysts.

Recent CMS policy changes phasing out the inpatient-only list and expanding coverage for procedures in ambulatory surgery centers are expected to increase the use of Pacira's EXPAREL in outpatient surgical settings. This area is poised for growth as surgery volumes in these settings outpace inpatient procedures, supporting top-line revenue growth in coming years.

Want the inside scoop on why analysts are calling this company undervalued? Hint: the story hinges on ambitious profit forecasts and a dramatic turnaround scenario. Curious about the game-changing financial targets driving this bullish price estimate? The real math behind these projections just might surprise you.

Result: Fair Value of $29.00 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, ongoing reliance on EXPAREL and potential delays in new product launches could still pose significant challenges to Pacira’s growth story.

Find out about the key risks to this Pacira BioSciences narrative.

Another View: SWS DCF Model Offers a Different Perspective

Taking a closer look with our SWS DCF model, the valuation story shifts. This approach suggests the market may be overlooking long-range cash flow potential. Could the true value be higher than most people think?

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Pacira BioSciences for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover undervalued stocks based on their cash flows. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Build Your Own Pacira BioSciences Narrative

If you would rather chart your own course or dig deeper into the numbers, you can craft a narrative in just a few minutes. Do it your way

A good starting point is our analysis highlighting 3 key rewards investors are optimistic about regarding Pacira BioSciences.

Looking for More Investment Ideas?

Staying ahead means acting now, so don’t let the next great opportunity pass you by. Use the Simply Wall Street Screener to pinpoint fresh stocks with unique potential.

• Spot rising stars making waves in healthcare innovation and tap into future breakthroughs with healthcare AI stocks.
• Lock in steady income streams and uncover reliable options among dividend stocks with yields > 3% for strong yields and lasting financial confidence.
• Ride the momentum in game-changing tech by targeting AI penny stocks set to shape tomorrow’s markets with artificial intelligence leadership.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com